Skip to main content
Equibles
HEPA logo

HEPA · Hepion Pharmaceuticals, Inc. · Documents

Track HEPA — free

Use HEPA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HEPA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.14 -0.18 (-57.55%) At close · May 13
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us.”
View the 10-Q filed Aug 13, 2026
Market Cap
$6.77M
Shares
90.22M
Volume · May 13 1.91M Avg daily vol (40 sessions) 7.18M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $8.28M 10-K filed Mar 12, 2026 Quarterly report FY2026 Q2 Net loss $1.25M 10-Q filed Aug 13, 2026
2026
Oct 9
Current report 8-K Events of Oct 6
Entered into a material agreement, Completed an acquisition or sale of assets, Unregistered sale of equity, Director or officer change, or executive pay

October 6, 2026, Hepion Pharmaceuticals acquired Gravitas Life Sciences, making it wholly owned, for $2,000,000 cash and 25,000,000 common shares based on $2,250,000 divided by closing stock price, plus $135,000; issuance is capped at 19.99%, with reductions settled in cash.

Read from the first part of this long document
Oct 2
Current report 8-K Events of Oct 1
Charter or bylaw amendment, or fiscal year change

Hepion Pharmaceuticals, Inc. increased authorized common stock to 750,000,000 shares and total authorized stock to 770,000,000 shares, including 20,000,000 preferred shares, effective October 1, 2026.

Sep 28
Current report 8-K Events of Sep 21
Change of auditor

On September 21, 2026, Hepion Pharmaceuticals, Inc. dismissed Grassi & Co., CPAs, P.C. and engaged Rosenberg Rich Baker Berman P.A. to audit its consolidated financial statements for the year ended December 31, 2026.

Mar 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $8.28M Diluted EPS -$0.88
2025
2024
Showing 1–50 of 197 documents
Key facts CIK 1583771 CUSIP 426897401 13F (30d) 1 filings 1 filers Visit website Investor relations